Lupin Limited

Lupin Digital Health releases results of its digital therapeutics study with ACS patients – ET HealthWorld

by
Lupin Digital Health releases results of its digital therapeutics study with ACS patients – ET HealthWorld

Chennai: Showing the efficacy of digital therapeutics (DTx) among patients with acute coronary syndrome (ACS) and post-percutaneous coronary interventions, Lupin Digital Health (LDH), a DTx platform, has released the results of a study in India. The one-year-long study was aimed at evaluating the efficacy of LDH’s digital therapeutics platform, Lyfe, on cardiovascular events, rehospitalisation, medication … Read more

Lupin announces the launch of its Digital Asthma Educator platform for patients – ET HealthWorld

by
Lupin announces the launch of its Digital Asthma Educator platform for patients – ET HealthWorld

Mumbai: Global pharma major Lupin Limited (Lupin) on Monday announced the launch of its Digital Asthma Educator platform for guiding patients on the correct technique of using inhalers. The educator platform has been launched as a part of the company’s long running umbrella programme, Joint Airways Initiative (JAI), for patients suffering from respiratory ailments. Commenting … Read more

What makes the latest pharma company to enter Nifty very different from its peers in the index?

by
What makes the latest pharma company to enter Nifty very different from its peers in the index?

ET Intelligence Group: An 80% gain in the stock of Divi’s Labs during the past five months has catapulted the company into the Nifty-50 Index. The Hyderabad-based pharma company, however, is quite different from peers Sun Pharma, Cipla and Dr Reddy’s Labs, and predecessors Lupin and Aurobindo Pharma in the index. It is the smallest … Read more

Over 158 applications for generic products pending with USFDA for approval: Lupin

by
Over 158 applications for generic products pending with USFDA for approval: Lupin

NEW DELHI:Drug firm Lupin remains bullish over its US business with over 158 applications for generic products pending with the US drug regulator for approval, as per the company’s annual report for 2019-20. Sharing information with company’s shareholders, Lupin MD Nilesh Gupta and CEO Vinita Gupta said the company’s US business stabilised last fiscal and … Read more